Oral candidiasis due to azole-resistant Candida albicans is an increasing problem in patients with AIDS who received prolonged periods of fluconazole prophylaxis. Infection with C. albicans is also frequent in patients undergoing transplantation. However, azole resistance has not been appreciated as a major problem for these patients, presumably because they receive a relatively short duration of fluconazole prophylaxis. We describe a case of disseminated candidiasis due to fluconazoleresistant C. albicans in a patient following marrow transplantation. Restriction fragment length polymorphism analysis with use of the C. albicans strain -specific Ca3 probe was performed on sequential isolates. Identical banding patterns were obtained, thereby confirming that a fluconazolesusceptible endogenous C. albicans acquired azole resistance during a brief exposure to the drug and subsequently caused disseminated infection. This observation raises questions regarding the incidence, significance, and mechanism of azole resistance in fungi causing infection in this population.
Infections caused by Candida are frequent following marrow diagnosed in 1993, and subsequently, he underwent six cycles of chemotherapy with cyclophosphamide, vincristine sulfate, transplantation, occurring in up to 11% of patients [1] . Infection due to azole-resistant Candida albicans, which has emerged prednisone, and doxorubicin, which resulted in complete remission. He did not receive any antifungal medications. In Novemas a problem in patients with AIDS who receive prolonged periods of prophylactic fluconazole, has recently been deber 1993, marrow examination revealed 15% lymphoid infiltration, and he was referred to our institution for transplantation. scribed in patients with cancer [2, 3] . The lack of resistance in C. albicans causing infection in this population is presumed He was treated with cyclophosphamide, antithymocyte globulin, and total body irradiation before infusion of marrow. Proto be due to the short duration of exposure to fluconazole.
We report a case of disseminated infection with azole-resistant phylaxis with oral fluconazole (400 mg/d) was begun on 31 January 1994, 8 days before transplantation (day 08). On day C. albicans that developed in a marrow transplant patient during /6, fever prompted discontinuation of fluconazole therapy and fluconazole prophylaxis. DNA typing of a series of sequential initiation of treatment with amphotericin B (0.5 mg/[kgrd]), isolates by means of restriction fragment length polymorphism ceftazidime, and vancomycin. Fevers continued with no growth (RFLP) analysis revealed that one strain of C. albicans acquired in blood cultures until therapy with high doses of methylpredresistance after only 23 days of fluconazole exposure.
nisolone sodium succinate was begun on day /10 for presumed graft vs. host disease. Renal insufficiency prompted the disconCase Report tinuation of amphotericin B therapy on day /9. On day /12, intravenous fluconazole therapy (400 mg/d) A 30-year-old man with T cell non-Hodgkin's lymphoma was started. Blood cultures on day /17 yielded C. albicans. received an unrelated, partially HLA (human leukocyte antiAmphotericin B therapy (0.5 mg/[kgrd]) was restarted, and gens)-mismatched marrow transplant in 1994. Lymphoma was fluconazole therapy was discontinued on day /20. His chest radiograph revealed interstitial infiltrates, and marrow examination showed no evidence of engraftment. Despite aggressive
Materials and Methods
Rectal swab specimens for cultures were taken before and during fluconazole prophylaxis, and blood specimens for cultures were obtained during febrile episodes (temperature, ú38.3ЊC). Samples were plated on Sabouraud dextrose agar and incubated for 48 hours at 37ЊC. Individual colonies of C. albicans were identified by germ tube testing and stored frozen at 070ЊC in 10% glycerol. Susceptibility testing for fluconazole was performed by the broth microdilution method at the Fungus Testing Laboratory, University of Texas Health Sciences Center at San Antonio [4] . Resistance was defined as an MIC of fluconazole of ú8 mg/mL [5] .
RFLP analysis with use of the C. albicans -specific probe Ca3 was used to determine the genetic relatedness of the nine isolates [6] . Genomic DNA was isolated after cell shearing with glass beads [7] . DNA was digested with the restriction enzymes EcoRI, BglII, BclI, and BamHI. Southern blotting was performed [8] . Filters were hybridized at 60ЊC with the Ca3 probe labeled by means of random priming, washed, and exposed to x-ray film [8] .
Results
Four rectal isolates (1 -4), four blood isolates (5 -8) , and one postmortem lung isolate (9) of C. albicans were obtained. The first isolate was obtained 1 day before the initiation of albicans was probed with Ca3. Genomic DNA from isolates 1 -9 were digested with the restriction enzyme EcoR1, subjected to electrophoresis, blotted, and probed with P 32 -labeled Ca3. l DNA digested with HindIII was used as markers, which are listed to the right of the figure. kB Å kilobases. the patient was receiving oral fluconazole therapy. Isolates 4 through 6 were obtained while the patient was receiving intravenous fluconazole therapy. Isolates 7 through 9 were obtained after fluconazole therapy had been discontinued. The susceptibilities of the isolates to fluconazole (MIC), the sites of culture specimens, the dates that the specimens were obtained, and the antifungal regimen are shown in figure 1 . After 14 days of fluconazole administration, the susceptible isolates were becoming resistant (MIC, 8 mg/mL). The MICs for the blood isolates were the highest (32 -64 mg/mL). The lung isolate was susceptible to fluconazole (MIC, 1 mg/mL).
RFLP analysis with use of the restriction enzyme EcoRI and the Ca3 probe revealed identical banding patterns, thereby / 9c3d$$oc47 09-19-97 08:28:29 cida UC: CID Discussion a limited phenomenon. This finding, along with the increased use of fluconazole prophylaxis, emphasizes our need to define The series of nine isolates from our patient represents one the mechanisms involved in the development of drug resisstrain of C. albicans that acquired resistance to fluconazole, in tance. Further studies should also address the epidemiology of varying amounts, over time. The methods we used to determine candidiasis in patients with cancer and transplant recipients fluconazole susceptibility and the genetic relatedness of Canso we can further refine our use of fluconazole as antifungal dida have been accepted and proven to be reliable. The MICs prophylaxis. were determined in a reference laboratory. RFLP analysis with use of the Ca3 probe has been used extensively for molecular typing of C. albicans [6, 9, 10] .
